Sickle Archives - Precision Medicine Group

Eric Hodgins joins Precision Medicine Group as CITO

Felix Nunez2025-04-15T14:16:38-04:00News, Press Releases|

Precision Medicine Group Names Pharma Services Innovator, Eric Hodgins, as Chief Information and Technology Officer

Industry veteran with a 30-year track record in building award-winning clinical and commercial technologies, Hodgins will focus on developing and enriching transformative technologies across Precision’s R&D and commercial services

BETHESDA, Md., April 16, 2025 – Precision Medicine Group (Precision), a leading provider of next-generation drug development, CRO and commercialization services, today announced the appointment of Eric Hodgins as the company’s Chief Information and Technology Officer, overseeing all of the company’s technology assets. (more…)

Precision Medicine Group Announces Key Leadership Appointments

Carlos Bonilla2024-10-22T12:31:59-04:00News, Press Releases|

Karl Deonanan appointed Chief Financial Officer
Matt DeZee named to newly established role, Chief Transformation and Strategy Officer

Bethesda, Md., October 23, 2024—Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced key leadership changes to support its next phase of growth. This includes the appointment of Karl Deonanan as Chief Financial Officer (CFO). Mr. Deonanan succeeds Matt DeZee, who has served as CFO of Precision since 2020 and will be transitioning to the newly created role of Chief Transformation and Strategy Officer (CTSO), effective immediately.

(more…)

Precision Medicine Group Welcomes Margaret Keegan as CEO

Carlos Bonilla2024-10-22T11:24:20-04:00News, Press Releases|

— Founding CEO Mark Clein named Executive Chairman; Mr. Clein and co-founder Ethan Leder to continue as Board Directors —

BETHESDA, MD., October 1, 2024 – Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced the appointment of Margaret Keegan as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately. Ms. Keegan succeeds Mark Clein, who is assuming the role of Executive Chairman. Mr. Clein co-founded Precision in 2012 as CEO and, together with co-founder Ethan Leder, purpose-built Precision to capitalize on the scientific and technological innovations that are transforming drug development and enabling widespread access to new, breakthrough therapies. Mr. Leder formerly served as Executive Chairman and will remain a member of the Board of Directors.

(more…)

Now Available On Demand: Cell & Gene Day, 2024

Morgan Labbree2024-05-02T12:45:24-04:00Cell & Gene Therapy, Events|

Cell and gene therapies are at a pivot point. These breakthrough therapies show big promise — but the business models to support these new advances are racing to catch up with the science. Can we keep up the pace in the current climate? Find out at Cell & Gene Day 2024, a free virtual event, WATCH ON DEMAND HERE.

(more…)

Conference: Gene Therapy for Rare Disorders (GTRD), 2024

Morgan Labbree2024-03-13T14:58:51-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s Gene Therapy for Rare Disorders on March 26-29, 2024, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization for gene therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below.

Precision will have a plenary speaking position on March 27, 2024, 8:30 – 9:00 am.
Precision’s Andy Kinley (VP, Innovation & Clinical Science, Precision for Medicine) will Chair the Clinical track session, “Clinical Endpoints for Rare Disease Studies,” on March 28, 2024, 11:15 am – 12:15 pm.

Connect with our Advanced Therapy experts

Schedule in-person or virtual meetings with our team

—

Plenary Speaking Position: What to Look Forward to for Gene Therapy in 2024
Precision | March 27, 2024, 8:30 – 9AM ET

Key Takeaways
- Market trends and expectations for Gene Therapies & Rare Diseases in 2024
- Predictions on Potential Approvals in 2024
- Innovative Trends & Technologies
- Evolution of CMC and manufacturing

Speakers:

[Moderator] Jake Greenwood, VP, Project Farma
Faraz Ali, CEO, Tenaya Therapeutics
Debs Phippard, CSO, Precision for Medicine
Frank Bugg, Global Head of BaseCamp Operations & Commercial, ElevateBio

Panel Discussion: Manufacturing Track: Capacity versus Capability – Moving Towards Innovative Manufacturing Processes
Precision | March 28, 2024, 11:15AM – 12:15PM ET

Andy Kinley, VP, Innovation & Clinical Science (Precision for Medicine) to Chair

Simon Fleming Joins Precision

Lisa Lewin2024-02-13T07:37:58-05:00Cell & Gene Therapy, News|

Simon Fleming has joined the Precision leadership team as Executive Vice President, Clinical Solutions. With over 30 years of experience leading global functions at a large CRO, Simon’s invaluable expertise will strengthen Precision across multiple fronts. He brings an impressive track record of performance, technical skills, and passion for aligning teams to drive research forward. We are confident Simon will make immediate strategic contributions as we continue advancing and accelerating the development of life-changing innovations.

Precision Medicine Group Releases Its Inaugural Environmental, Social and Governance (ESG) Report

Lisa Lewin2023-12-14T08:40:44-05:00Cell & Gene Therapy, News, Thought Leadership|

Precision is proud to have published our inaugural 2023 Environmental, Social and Governance (ESG) Report, reflecting the company’s ongoing efforts to do better for our people, in our practices, and with the broader community at large. This year’s report shares key achievements, performance metrics, and steps we have taken to enhance sustainability throughout the company, including:

· Engaging internal and external stakeholders in our company’s first ESG materiality assessment to identify and prioritize our material issues

· Defining Precision’s approach to ESG in our company’s ESG Strategy Statement · Creating a three-year strategic ESG Roadmap for advancing our performance across environmental, social, and governance issues · Initiating energy efficiency projects and standards across our facilities

· Implementing implicit bias training for our Executive Leadership Team and Human Resources leaders

· Contributing volunteer hours by over 425 employees and over $250,000 in donations to more than 70 charitable foundations and causes

(more…)

White Paper: Unleashing the Power of Precision Medicine: Radioligand Therapy

Morgan Labbree2023-11-03T16:36:34-04:00Cell & Gene Therapy, News, Thought Leadership|

This article was originally published on This Month in Transformative Medicine on October 17, 2023

The current standard of cancer care has saved many lives, but these methods often come with incredibly difficult side effects. Advancements in technology have brought new options to cancer care that hope to provide meaningful outcomes while minimizing the impact to the patient’s quality of life.

In this white paper Anshul Mangal, President of Project Farma (PF) & Precision ADVANCE, and Sumit Verma, Co-founder and Partner at Orchestra Life Sciences, discuss the power and potential of radioligand therapies and its impact on the treatment of a number of cancers.

(more…)

On Demand: State of the Union for Advanced Therapies

Morgan Labbree2023-11-14T10:42:38-05:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar convened industry leaders to discuss the current state of the industry, and the future of advanced therapies including innovations in research and development, going from treating rare diseases to prevalent conditions, continued investment, and next-generation technologies. The panelists also discussed manufacturing and talent bottlenecks, and innovative reimbursement payment models. This discussion was moderated by Anshul Mangal: President (Precision ADVANCE & Project Farma), and included insights from Dan Kirby: Chief Commercial Officer (Orca Bio), Deborah Phippard: CSO (Precision for Medicine), Devyn Smith: CEO (Arbor Bio), Helen Sabzevari: President & CEO (Precigen) and Chad Salisbury: SVP (Project Farma).

(more…)

White Paper: Scaling Hope: The Growth of the Allogeneic Cell Therapy Sector

Morgan Labbree2023-09-22T15:39:39-04:00Cell & Gene Therapy, News, Thought Leadership|

In the rapidly evolving landscape of advanced therapies, allogeneic cell therapies have emerged as a promising avenue for addressing various disorders, including hematological malignancies, neurological conditions, and autoimmune or inflammatory diseases. With a number of clinical trials underway to evaluate their efficacy, allogeneic cell therapies hold significant potential in reshaping the way we approach treating numerous diseases.

In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and John Khoury, Executive Vice President of Project Farma (PF), discuss the growth of the allogeneic cell therapy sector and its impact on patient access.

(more…)